PTTG3P and neoplasm: Intriguingly, the treatment of Hippo pathway inhibitor, XMU-MP-1 (inhibiting MST1/2), could not recover the effect of PTTG3P on proliferation, apoptosis, and tumor growth (Figure 4I,J).